Skip to main content
. Author manuscript; available in PMC: 2012 Dec 21.
Published in final edited form as: J Thorac Oncol. 2009 Apr;4(4):527–533. doi: 10.1097/JTO.0b013e31819c7daf

TABLE 4. Comparison of Trials of PET with TRT in LD-SCLC.

Chemotherapy RT n RR OS (months)
E2596 Paclitaxel 170 mg/m2 IV d2 Cisplatin 60 mg/m2 IV d1 Etoposide 80 mg/m2 IV d1–3 Paclitaxel 135 mg/m2 IV d2 c3–4 63 Gy starting cycle 3 61 79% 15.7
Ettinger39 Paclitaxel 135 mg/m2 IV d1 c1–2 Cisplatin 60 mg/m2 IV d1 Etoposide 60 mg/m2 IV d1 Etoposide 80 mg/m2 PO d2–3 Paclitaxel 175 mg/m2 IV c 3–4 45 Gy starting cycle 1 55 92% 24.7
Bremnes38 Paclitaxel 175 mg/m2 IV d1 c1–2 Cisplatin 50 mg/m2 IV d1 Etoposide 100 mg/m2 IV d1 Etoposide 100 mg/m2 PO bid d2–5 42 Gy starting cycle 3 39 92% 21.0

PET, cisplatin plus etoposide plus paclitaxel; TRT, thoracic radiotherapy; OS, overall survival; SCLC, small cell lung cancer; LD, limited stage disease; RR, response rate; RT, radiotherapy.